LEANOX: Lean body mass normalization of oxaliplatin-based chemotherapy for patients with stage III colon cancer treated in adjuvant setting: Impact on oxaliplatin-induced sensitive neurotoxicity—A multicenter phase II randomized trial.
Pharmacology, Toxicology and Pharmaceutical Science
1
10%
Unknown
5
50%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2024.
All research outputs
#17,767,509
of 26,241,678 outputs
Outputs from Journal of Clinical Oncology
#18,915
of 22,785 outputs
Outputs of similar age
#285,123
of 493,139 outputs
Outputs of similar age from Journal of Clinical Oncology
#301
of 353 outputs
Altmetric has tracked 26,241,678 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,785 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.4. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 493,139 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 353 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.